HOOK - HOOKIPA Pharma achieves $5M milestone payment under collaboration with Gilead

• HOOKIPA Pharma ( NASDAQ: HOOK ) on Wednesday said it had achieved a $5M milestone payment under its collaboration agreement with Gilead Sciences ( GILD ).
• Shares of the micro-cap clinical-stage biopharma rose 3.8% to $0.83 in afternoon trade.
• "HOOKIPA completed and delivered a regulatory support package for Gilead’s Phase 1 clinical trial of an investigational therapeutic vaccine for chronic hepatitis B using HOOKIPA’s arenaviral platform," HOOK said in a statement .
• The first participant in the early-stage trial is expected to be dosed in 2023.
• The hepatitis B program is one of two development programs in HOOK's collaboration and license agreement with GILD.

For further details see: